Entrada Therapeutics Inc

Entrada Therapeutics maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet shows total assets of $377.4 million against total liabilities of $71.2 million, leaving total equity at $306.1 million. Liquidity is supported by cash and equivalents of $90.4 million, which stands against an operating cash flow burn of $128.5 million for the period. The current ratio is not explicitly provided, but the absence of debt and significant cash reserves suggest manageable short-term obligations despite the negative cash flow. The market capitalization is $232.8 million, trading at a price-to-book ratio of 0.76, indicating the market values the company below its tangible book value.

Profitability metrics reflect the typical profile of a pre-commercial biotechnology firm, with significant losses. Net income stands at -$143.8 million, and operating income is -$157.9 million. Return on equity is -54.26%, and return on assets is -44.02%. These negative returns are consistent with the high research and development expenditures required in the biotechnology sector before product commercialization. The company generated $25.4 million in revenue, which is insufficient to cover operating costs, leading to the substantial net loss. The EV/EBITDA ratio is negative, further highlighting the lack of current earnings.

Revenue $875.0k, −95,7% YoY; Operating income −94,1% YoY.

• ▍Revenue $875.0k, −95,7% YoY
• ▍Operating income −94,1% YoY
• ▍Net income −128,9% YoY
• ▍Free cash flow −122,0% YoY
• ▍Net margin -4539.1%

Revenue $1.3M, −96,5% YoY; Operating income −619,4% YoY.

• ▍Revenue $1.3M, −96,5% YoY
• ▍Operating income −619,4% YoY
• ▍Net income −3 562,8% YoY
• ▍Free cash flow −2 643,9% YoY
• ▍Net margin -3014.9%

Revenue $1.6M, −91,8% YoY; Operating income −117,2% YoY.

• ▍Revenue $1.6M, −91,8% YoY
• ▍Operating income −117,2% YoY
• ▍Net income −214,5% YoY
• ▍Free cash flow −211,2% YoY
• ▍Net margin -2734.4%

Revenue $1.9M, −97,9% YoY; Operating income −187,7% YoY.

• ▍Revenue $1.9M, −97,9% YoY
• ▍Operating income −187,7% YoY
• ▍Net income −178,3% YoY
• ▍Free cash flow −177,0% YoY
• ▍Net margin -2210.4%

Revenue $20.6M; Operating income -$21.8M.

• ▍Revenue $20.6M
• ▍Operating income -$21.8M
• ▍Net margin -84.4%

Revenue $37.4M; Operating income -$5.9M.

• ▍Revenue $37.4M
• ▍Operating income -$5.9M
• ▍Net margin 3.0%

Revenue $19.6M; Operating income -$21.7M.

• ▍Revenue $19.6M
• ▍Operating income -$21.7M
• ▍Net margin -71.7%

Revenue $94.7M; Operating income $53.4M.

• ▍Revenue $94.7M
• ▍Operating income $53.4M
• ▍Net margin 58.1%

Revenue $25.4M, −87,9% YoY; Operating income −435,9% YoY.

• ▍Revenue $25.4M, −87,9% YoY
• ▍Operating income −435,9% YoY
• ▍Net income −319,0% YoY
• ▍Free cash flow −312,3% YoY
• ▍Net margin -565.5%

Revenue $210.8M, +63,4% YoY; Operating income +1 586,8% YoY.

• ▍Revenue $210.8M, +63,4% YoY
• ▍Operating income +1 586,8% YoY
• ▍Net income +1 081,7% YoY
• ▍Free cash flow +800,7% YoY
• ▍Net margin 31.1%

Revenue $129.0M; Operating income +96,8% YoY.

• ▍Revenue $129.0M
• ▍Operating income +96,8% YoY
• ▍Net income +92,9% YoY
• ▍Free cash flow +90,1% YoY
• ▍Net margin -5.2%

Operating income −90,2% YoY; Net income −85,0% YoY.

• ▍Operating income −90,2% YoY
• ▍Net income −85,0% YoY
• ▍Free cash flow −75,0% YoY